5 news items
EMa Grants Lisata Therapeutics Paediatric Investigation Plan Waiver For Certepetide In Pancreatic Cancer
LSTA
20 May 24
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
LSTA
20 May 24
Agency (the "EMA") on a Paediatric Investigation Plan ("PIP") for Lisata's lead investigational product, certepetide (formerly LSTA1), in pancreatic
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
LSTA
2 May 24
, is an investigational drug designed to activate a novel uptake pathway that allows
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
LSTA
23 Apr 24
9.9-22.8). About LSTA1 LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
LSTA
3 Apr 24
, is an investigational drug designed
- Prev
- 1
- Next